Smartleaf Asset Management’s Aquestive Therapeutics AQST Stock Holding History

Smartleaf Asset Management’s Portfolio AQST Stock Details AQST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4	Buy	+1	New	+$4	﹤0.01%	3495

Other funds holding AQST

BCM

Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Smartleaf Asset Management's AQST Position: Q1 2026 in Review

Smartleaf Asset Management opened a new position in Aquestive Therapeutics (AQST) in Q1 2026: 1 share worth $4. The stake represents ﹤0.01% of the portfolio and ranks #3495 among its holdings.

179 funds tracked by Wall St. Rank hold AQST as of Q1 2026.

Smartleaf Asset Management held 1 share of Aquestive Therapeutics worth $4 as of Q1 2026.
Aquestive Therapeutics was a new Smartleaf Asset Management position in Q1 2026.
Aquestive Therapeutics made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q1 2026, its #3495 holding.
179 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q1 2026.

Based on Smartleaf Asset Management's 13F filing for Q1 2026, filed 15 May 2026.